Crossmark

Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity

Crossref DOI link: https://doi.org/10.1007/s00702-018-1911-3

Published Online: 2018-07-31

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dressler, Dirk

Pan, Lizhen

Adib Saberi, Fereshte
License Information

Text and Data Mining valid from 2018-07-31
More Information

Article History

Received: 26 April 2018

Accepted: 24 July 2018

First Online: 31 July 2018

Compliance with ethical standards

:

: DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. LP has nothing to declare. FAS received reimbursement from Abbot, Abbvie, Almirall, Allergan, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Merz, Orion, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med, UCB.